Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ida Paris

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|July 29, 2025
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective studyGuido Maria Giuffrè, Luisa Carbognin, Giovanna Masone Iacobucci, et al.
Journal of the National Cancer Institute|May 15, 2020
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Fabiola Giudici, Mario Giuliano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Journal of Personalized Medicine|April 3, 2021
Development of a Digital Research Assistant for the Management of Patients' Enrollment in Oncology Clinical Trials within a Research HospitalAlfredo Cesario, Irene Simone, Ida Paris, et al.
Journal of Personalized Medicine|December 23, 2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient SeriesArmando Orlandi, Elena Iattoni, Laura Pizzuti, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
NPJ Precision Oncology|January 22, 2025
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
NPJ Breast Cancer|February 5, 2024
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
NPJ Breast Cancer|October 31, 2023
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
Journal of Personalized Medicine|August 25, 2023
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant ChemotherapyAntonio Franco, Alba Di Leone, Marco Conti, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|July 29, 2025
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective studyGuido Maria Giuffrè, Luisa Carbognin, Giovanna Masone Iacobucci, et al.
Journal of the National Cancer Institute|May 15, 2020
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Fabiola Giudici, Mario Giuliano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Journal of Personalized Medicine|April 3, 2021
Development of a Digital Research Assistant for the Management of Patients' Enrollment in Oncology Clinical Trials within a Research HospitalAlfredo Cesario, Irene Simone, Ida Paris, et al.
Journal of Personalized Medicine|December 23, 2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient SeriesArmando Orlandi, Elena Iattoni, Laura Pizzuti, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
NPJ Precision Oncology|January 22, 2025
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
NPJ Breast Cancer|February 5, 2024
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
NPJ Breast Cancer|October 31, 2023
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancerAlessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
Journal of Personalized Medicine|August 25, 2023
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant ChemotherapyAntonio Franco, Alba Di Leone, Marco Conti, et al.
Pageof 10